Johnson & Johnson (JNJ)

113.94
0.21 0.18
NYSE : Health Care
Prev Close 114.15
Open 114.51
Day Low/High 113.80 / 114.77
52 Wk Low/High 95.95 / 126.07
Volume 7.28M
Avg Volume 7.07M
Exchange NYSE
Shares Outstanding 2.72B
Market Cap 310.68B
EPS 5.60
P/E Ratio 20.04
Div & Yield 3.20 (2.80%)

Latest News

Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

What to Watch This Week: Trump's Presidency, Alphabet Earnings

What to Watch This Week: Trump's Presidency, Alphabet Earnings

For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

Ethicon Announces Acquisition Of Megadyne Medical Products, Inc.

Ethicon Announces Acquisition Of Megadyne Medical Products, Inc.

Complements and expands Ethicon's advanced energy portfolio with broad range of innovative electrosurgical tools

Intermediate Trade: Johnson & Johnson

Intermediate Trade: Johnson & Johnson

After an up-and-down year, this household name is as strong as ever.

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

Here's the Company That Helped Design Work Spaces for Facebook and Microsoft

Here's the Company That Helped Design Work Spaces for Facebook and Microsoft

We toured the company helping design cool workspaces for Fortune 500 companies like Facebook and Microsoft.

Here's Why Johnson & Johnson Shares Are Poised for a Rally

Here's Why Johnson & Johnson Shares Are Poised for a Rally

Shares of Johnson & Johnson are poised for a rally as the stock is currently trading about 8% off its 52-week high.

Could Johnson & Johnson Rip Higher by 20%?

Could Johnson & Johnson Rip Higher by 20%?

It may just happen. Here is why.

JNJ, Actelion Reportedly Move Closer to a Deal

JNJ, Actelion Reportedly Move Closer to a Deal

A final deal could come as soon as this month, Bloomberg reported.

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Shares of J&J and Procter & Gamble Could Be Ready to Break Out

Shares of J&J and Procter & Gamble Could Be Ready to Break Out

After a period of consolidation, several personal care products companies look like they are about to rally.

Johnson & Johnson CEO Gorsky Discusses What Drove the Stock in 2016

Johnson & Johnson CEO Gorsky Discusses What Drove the Stock in 2016

Johnson & Johnson CEO Alex Gorsky discusses the 16% rise in the company's stock over the last year.

The Charts Show These Two Blue Chips Are Poised for a Big Breakout

The Charts Show These Two Blue Chips Are Poised for a Big Breakout

These four personal-products stocks are poised for profits.

Technology Rules as Only S&P Sector Hitting a New High

Technology Rules as Only S&P Sector Hitting a New High

Of the 11 S&P 500 sectors, technology leads followed by gain from health care and consumer discretionary stocks. Here's how you trade these sectors using exchange-traded funds.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Jim Cramer ponders how too few stocks are doing too much in the Dow's race to 20,000 and how there isn't enough GANG to go with all the FANG.

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Disney and Goldman are doing a lot of the heavy lifting.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Thursday's announcement marks Pfizer's third proposed biosimilar pipeline molecule to announce positive top-line results within the past four months.

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.